Loading...
Torcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, has helped to raise HDL-cholesterol levels in clinical trials. However, it has raised blood pressure and has also failed on more important trial endpoints: Torcetrapib/atorvastatin combination therapy was associated with worse cardiovascular and mortality outcomes than was atorvastatin monotherapy in the now-halted ILLUMINATE trial, and combination therapy showed no advantage in limiting coronary disease progression (assessed by intravascular ultrasound) in the ILLUSTRATE trial (Journal Watch Cardiology Mar 26 2007).
Now, we have results from the manufacturer-funded RADIANCE 1 trial of torcetrapib in patients with heterozygous familial hypercholesterolemia. It started with a…